{
    "nct_id": "NCT04825288",
    "official_title": "A Phase I/II Randomized, Double-blind, Placebo-controlled Trial (1-BETTER) Examining XB2001 (Anti-IL-1⍺ True Human Antibody) in Combination With ONIVYDE + 5-FU/LV (+Folinic Acid) in Advanced Pancreatic Cancer",
    "inclusion_criteria": "* Histologically or cytologically confirmed pancreatic adenocarcinoma of exocrine pancreas that is metastatic, unresectable, or recurrent\n* At least one measurable lesion according to Response Evaluation Criteria in Solid Tumor V1.1\n* Documented disease progression after one prior gemcitabine-based therapy OR one FOLFIRINOX and gemcitabine combination therapy\n* Eastern Cooperative Oncology Group (ECOG) performance of 0 or 1 or Karnofsky performance status (KPS) ≥ 70\n* Adequate hepatic, renal and bone marrow function\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Clinically significant decrease in performance status (medical records) within 2 weeks of intended first dose administration\n* Clinically significant GI disorders\n* Severe arterial thromboembolic events less than 6 months before inclusion\n* Prior Whole Brain Radiation Therapy (WBRT)\n* Evidence of brain metastases\n* NYHA Class III or IV congestive heart failure, ventricular arrhythmias or uncontrolled blood pressure (defined as ≥ 160/100 mm Hg)\n* Use of strong CYP3A4 inducers or inhibitors and/or UGT1A1 inhibitors within 14 days prior to Visit 1/Baseline visit.",
    "miscellaneous_criteria": ""
}